{"entity":{"id":"nct06082102","kind":"trial","name":"Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma","aka":[],"tldr":"A phase 3 trial of Orelabrutinib, Rituximab and Lenalidomide in non-Hodgkin lymphoma, run by Beijing InnoCare Pharma Tech Co., Ltd., now recruiting.","summary":"Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma is a phase 3 interventional study registered as NCT06082102 by Beijing InnoCare Pharma Tech Co., Ltd., with 324 participants planned, started 2023-12-19 and due to reach its primary completion in 2028-08-31. Interventions recorded: Orelabrutinib, Rituximab and Lenalidomide.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06082102","url":"https://clinicaltrials.gov/study/NCT06082102"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma","marginal-zone-lymphoma"],"sections":[],"technologies":["kinase-inhibitors","monoclonal-antibody","protac-degrader"],"targets":[],"drugs":["orelabrutinib","rituximab","lenalidomide"],"companies":["innocare"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06082102","phase":"3","setting":"A Randomized, Controlled, Open-label, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Orelabrutinib Plus Rituximab Versus Lenalidomide Plus Rituximab in Relapsed/Refractory Marginal Zone Lymphoma","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","started":"2023-12-19","startedType":"actual","enrolled":324,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06082102/","neighbours":{"cancer":[{"id":"malt-lymphoma","kind":"cancer","name":"Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","route":"/cancers/malt-lymphoma/"},{"id":"marginal-zone-lymphoma","kind":"cancer","name":"Marginal zone lymphoma","route":"/cancers/marginal-zone-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"},{"id":"orelabrutinib","kind":"drug","name":"Orelabrutinib","route":"/drugs/orelabrutinib/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"}],"company":[{"id":"innocare","kind":"company","name":"InnoCare Pharma","route":"/companies/innocare/"}]}}